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Abstract 
Over the past decade, there has been a major shift in chemotherapy from non-specific 
cytotoxic drugs to molecular targeted drug therapies. As more molecular targeted therapies 
are developed, new types of cardiovascular toxicities induced by targeted therapies are a 
growing problem. Cardiotoxicity induced by the human epidermal growth factor receptor-2 
inhibitor trastuzumab manifests as decreased left ventricular ejection fraction. In contrast to 
anthracycline treatment, most cardiac events occur during trastuzumab treatment, but are 
reversed quickly when treatment is interrupted and cardiac intervention is established. 
Vascular endothelial growth factor pathway inhibitors decrease vascular tone, leading to 
hypertension. After drug initiation, the early detection and aggressive pharmacological 
management of hypertension are necessary to avoid severe complications. Cardiovascular 
safety is an emerging challenge in patients treated with newer generations of BCR-ABL 
inhibitors. Although rare, dasatinib-induced pulmonary hypertension is potentially fatal. 
Vascular events including cardiac and cerebral ischemic events and peripheral arterial 
occlusive disease have emerged as a new type of toxicity in patients treated with ponatinib 
and nilotinib. Thus, a wide variety of cardiovascular toxicities have been observed in patients 
treated with targeted drugs and have become a critically important topic of discussion for the 
practicing oncologist and cardiologists. Awareness of the potential side effects, recognition of 
signs and symptoms, and the establishment of therapeutic strategies are all crucial to 
providing quality patient care.  
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Introduction 
The introduction of molecular targeted therapies has revolutionized cancer therapy and 
contributed to a steady decline in cancer deaths since the late 1990s. However, both cardiac 
and vascular toxicities have been reported for these agents, some as expected on-target effects 
and others as off-target toxicities (Table 1). This review focuses on the cardiovascular 
toxicities associated with three categories of targeted therapy agents: 1) human epidermal 
growth factor receptor-2 (HER2) inhibitors; 2) vascular endothelial growth factor (VEGF) 
signaling pathway inhibitors; and 3) BCR-ABL kinase inhibitors. 
 
1. HER2 inhibitors  
Trastuzumab, the first clinically used humanized monoclonal antibody directed against the 
erythroblastic leukemia viral oncogene homolog 2 (ErbB2, also known as HER2), has 
revolutionized the treatment of metastatic HER2-positive breast cancer. Although early phase 
II trials indicated high efficacy and a favorable safety profile, an unexpectedly high rate of 
adverse cardiac events during the first phase III trial was identified; 27% of patients receiving 
concomitant trastuzumab and anthracycline-containing chemotherapy developed cardiac 
dysfunction compared with 8% of patients receiving anthracycline alone (1–3). The rates of 
cardiac dysfunction in patients who received paclitaxel and trastuzumab versus paclitaxel 
alone were 13% and 1%, respectively. The incidence of New York Heart Association 
(NYHA) class III or IV heart failure was highest among patients receiving anthracycline, 
cyclophosphamide, and trastuzumab, 16%, compared with 3% for patients receiving 
anthracycline and cyclophosphamide alone. In subsequent trials, the incidence of cardiac 
events was reduced through changes in chemotherapy regimens, stricter patient selection, and 
close cardiac assessment (4). However, cardiotoxicity remains a significant problem in 
clinical practice that is likely to increase as new agents are approved and exposure times 
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increase through improved survival.  
 
1.1 ErbB2 signaling in the heart 
The importance of ErbB receptors and their ligand neureglin-1 (NRG-1) during development 
is evident from analyses of genetically modified mice. The deletion of ErbB2 (5), ErbB4 (6), 
and NRG-1(7) led to embryonic lethality caused by cardiac malformations (5). Conditional 
mutations of ErbB2 in cardiomyocytes resulted in the development of spontaneous dilated 
cardiomyopathy with left ventricular chamber dilation, wall thinning, and reduced 
contractility (8,9). Additionally, cardiomyocytes isolated from these conditional mutants were 
more susceptible to anthracycline toxicity (9).  
NRG-1 is expressed by the endocardium and endothelium of the cardiac 
microvasculature (10). ErbB2 functions as a non-ligand-binding, pre-activated co-receptor; in 
the myocardium, it heterodimerizes with ErbB4 upon NRG-1-induced activation (11). The 
binding of NRG1 to ErbB4 increases its kinase activity and leads to heterodimerization with 
ErbB2 or homodimerization with ErbB4 and stimulation of the intracellular signal 
transduction pathways, such as the phosphoinositide 3-kinase (PI3K)/Akt, Ras/extracellular 
signal-regulated kinases (ERK), and proto-oncogene tyrosine-protein kinase (Src)/focal 
adhesion kinase (FAK) pathway. NRG-1/ErbB signaling induces cardiomyocyte growth and 
proliferation via PI3K/Akt and ERK1/2 signaling. It also protects cardiomyocytes from 
apoptosis and stimulates nitric oxide (NO) production through PI3K/Akt signaling (Figure 1) 
(11). 
NRG-1/ErbB signaling also plays important roles in adaptation of the heart to injury 
in adults as well as attenuating myofibrillar disarray and promoting cell survival (10,12). In 
animal models of myocardial ischemia, doxorubicin cardiomyopathy, viral myocarditis, and 
rapid pacing-induced heart failure, cardiac performance and survival were improved by the 
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infusion of recombinant NRG-1 receptor-active peptide (13). Furthermore, NRG-1 
administration to adult mice promotes myocardial regeneration by inducing mononucleated 
cardiomyocytes to divide, improving cardiac function after myocardial infarction (14). Thus, 
exogenous NRG-1 agents have been developed and are being evaluated in clinical trials. Early 
clinical trials with the epidermal growth factor (EGF)-like domain of NRG in heart failure 
have demonstrated safety and efficacy (15,16), and is currently tested in phase III clinical trial. 
Recent work from D’Uva et al. clearly showed that augmentation of ErbB2 signaling 
awakened a dormant regenerative window in juvenile and adult mouse cardiomyocytes (17). 
ErbB2 was necessary for NRG-1-induced cardiomyocyte proliferation during the transient 
postnatal regenerative window and became limiting as cardiomyocytes stopped dividing. 
They showed that transient reactivation of ErbB2 signaling in adult mice stimulated 
cardiomyocyte proliferation and allowed anatomical and functional regeneration of hearts 
after myocardial infarction. Taken together, these data point toward a fundamental role of 
ErbB2 signaling in cardiac development during embryogenesis and in cardiomyocyte survival, 
especially in situations of stress by promoting the survival and regeneration pathways that 
maintain cardiac function.  
 
1.2 Management of anti-HER2 therapy-associated cardiotoxicity  
Initially, the incidence of cardiotoxicity was reportedly high when trastuzumab was 
administered concurrently with anthracyclines in a trial of metastatic breast cancer (2). 
Applying trastuzumab sequentially after anthracyclines or using an anthracycline-free 
chemotherapy regimen substantially reduced the clinical heart failure rate. Based on several 
large-scale trials of adjuvant therapy in breast cancer, the rate of cardiac dysfunction was 
7.1-18.6%, with severe overt heart failure (NYHA class III and IV) rates of 0.4-4.1% (18–20). 
When trastuzumab was used concomitantly with non-anthracycline chemotherapy, the cardiac 
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dysfunction rates were 3.2-9.4%, with 0.4-0.5% developing clinical heart failure (20–22). 
These data indicate that concomitant or previous use of anthracyclines substantially increases 
trastuzumab-associated cardiotoxicity. Long-term follow-up data showed that, in contrast to 
anthracyclines, most cardiac events occurred during trastuzumab treatment and were reversed 
quickly when treatment was interrupted and cardiac intervention was established (23–25). 
However, in most trials, patients were relatively young and had normal or nearly normal 
cardiac function without a significant cardiovascular history. A large cohort of breast cancer 
patients at least 66 years old looked at the rate of cardiotoxicity in patients who received 
trastuzumab and chemotherapy (anthracycline and/or taxane) compared with chemotherapy 
alone (26). Among trastuzumab-treated patients, the rate of congestive heart failure was 
29.4% compared with 18.9% in nontrastuzumab users (P < 0.001). Among trastuzumab users, 
older age (age >80 years) was one of the factors that increased the risk of congestive heart 
failure (26). Another large cohort study of elderly women aged 67–94 years of age showed 
that adjusted 3-year heart failure or cardiomyopathy incidence rates were higher for patients 
receiving trastuzumab (32.1%) and anthracycline plus trastuzumab (41.9%) compared with no 
adjuvant therapy (18.1%, P < 0.001) (27). Thus, the incidence of cardiotoxicity in older 
patients treated with trastuzumab is expected to be higher than in the overall population 
evaluated in large clinical trials. Therefore, cardiac risk assessment, cancer recurrence risk, 
and discussion between cardiologists and oncologists should take place prior to making 
decisions about cancer treatment, and long-term continuous cardiac monitoring is especially 
advised in this population. 
Previous studies revealed several risk factors for anti-HER2 drug-induced 
cardiotoxicity, including previous anthracycline exposure, hypertension, a low baseline left 
ventricular ejection fraction (LVEF), and older age (28). One of the most relevant clinical 
implications of trastuzumab cardiotoxicity is treatment interruption, which is associated with 
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increased cancer recurrence (29). The clinical benefit from HER2 inhibitors needs to be 
balanced against cardiotoxicity. For patients with advanced cancer, the balance between 
trastuzumab benefit and heart failure risk may remain finely balanced, if trastuzumab was 
effective. Careful consideration should be given before trastuzumab discontinuation. It 
remains unclear whether an asymptomatic LVEF decline is predictive of clinical heart failure 
among patients treated with HER2 inhibitors. Therefore, some patients with reduced LVEF 
may have the opportunity to continue trastuzumab under optimal cardioprotective treatment. 
More recently, a double-blinded, placebo-controlled trial showed that for patients with 
early-stage HER2-positive breast cancer, prophylactic treatment with angiotensin-converting 
enzyme inhibitors (ACE inhibitors) or β-blockers attenuated cardiac dysfunction associated 
with trastuzumab therapy by reducing the decrease in LVEF; however, the treatment could 
not prevent trastuzumab-related left ventricular remodeling, the primary outcome of this trial 
(30). Larger studies with longer follow-up are required to reaffirm the protective effects of 
ACE inhibitors and β-blockers on cardiac function and to determine the impact of such 
interventions on cardiovascular outcomes.  
 
2. VEGF signaling pathway inhibitors 
2.1 VEGF inhibitor-induced hypertension 
Incidence 
Soon after the VEGF pathway inhibitors entered the clinical arena, it became evident that 
hypertension was a serious unexpected cardiovascular toxicity (31). The VEGF signaling 
inhibitors and their cardiovascular side effects are summarized in Table 1. Systemic arterial 
hypertension induction or worsening is caused by all of these drugs and is the most common 
cardiovascular side effect, with a reported 20-44% incidence of overall hypertension and a 
6-17% incidence of high-grade hypertension (32). VEGF signaling inhibitor-induced 
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hypertension is not a side effect of treatment, but rather a mechanism-dependent on-target 
toxicity (33). This has led to the concept that hypertension may serve as a surrogate for the 
effective anti-angiogenic response and could be a biomarker of better outcomes (34–36).  
 
Potential mechanisms of VEGF inhibitor-induced hypertension 
VEGF inhibitors induce an imbalance between vasodilation and vasoconstriction; as a 
consequence, they increase the peripheral vascular resistance and blood pressure (31,37,38). 
VEGF binding to VEGF receptors (VEGFRs) initiates a tyrosine kinase signaling cascade 
that leads to increased proliferation, survival, permeability, and migration (Figure 2) (39). 
VEGFR2 activation leads to PI3K recruitment followed by protein kinase B (PKB)/Akt 
activation and endothelial NO synthase (eNOS) phosphorylation, resulting in increased NO 
production. In a paracrine fashion, NO diffuses to vascular smooth muscle cells, where it 
activates guanylyl cyclase with a consequent increase in cyclic guanosine monophosphate 
(cGMP) production and vasodilation, thus playing an important role in maintaining vascular 
tone (40). VEGF also leads to the production of another vasodilator, prostacyclin I2 (PGI2), 
and decreases endothelin-1 (ET-1) level, a potent vasoconstrictor. Thus, VEGF inhibitors 
decrease the vascular tone, leading to hypertension (31,37,38).  
Another possible mechanism is a net reduction in tissue microvessel density and 
capillary rarefaction (loss of parallel capillary circulation), resulting in increased afterload 
and thereby contributing to the pathogenesis of hypertension (41). VEGF is an important 
mediatorof endothelial cell proliferation and survival. Therefore, the inhibition of VEGF 
signaling would cause vascular rarefaction and endothelial cell apoptosis (38). 
  
Monitoring and treatment of hypertension 
The exact risk factors that predispose patients to VEGF inhibitor-induced hypertension 
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remain to be established. However, preexisting hypertension has been considered an 
independent risk factor for hypertension after VEGF pathway inhibition. In addition, an age > 
60 years and elevated body mass index emerged as independent risk factors (38,42,43).  
The recommendations for clinical practice are; (1) a formal risk assessment for 
existing cardiovascular disease and potential cardiovascular complications before VEGF 
pathway inhibitor treatment; (2) active monitoring for blood pressure elevations 
and cardiac toxicity with more frequent assessments during the first therapy cycle; and (3) 
aggressive management of blood pressure elevations and early symptoms and signs of cardiac 
toxicity to prevent clinically limiting complications (44,45). Because the development of 
hypertension in response to VEGF pathway inhibition can occur within hours to days, close 
monitoring of blood pressure after the initiation of a VEGF signaling inhibitor is mandatory 
(44). In patients with preexisting hypertension, the blood pressure target for initiating VEGF 
inhibitor treatment should be < 140/90 mmHg, or lower in cases of overt proteinuria (32,46). 
After the initiation of VEGF inhibitors, the early detection and aggressive 
pharmacological management of hypertension are necessary to avoid severe complications 
(46). ACE inhibitors, angiotensin II receptor blockers, and β-blockers are reasonable as 
first-line therapies for VEGF inhibitor-induced hypertension (32,44,46). As the 
non-dihydropyridine calcium channel blockers (verapamil and diltiazem) inhibit cytochrome 
P450 3A4 and result in increased plasma concentrations of many VEGF inhibitors, they 
should preferably be avoided. If blood pressure is uncontrolled (systolic blood pressure ≥ 160 
mmHg or diastolic blood pressure ≥ 100 mmHg), dose reduction and reinforcement of 
antihypertensive treatment or discontinuation of VEGF inhibitors should be considered 
(32,37,46).  
 
2.2 VEGF inhibitor-induced thromboembolism 
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Numerous studies have shown that arterial and venous thromboembolic events are increased 
in cancer patients treated with VEGF inhibitors. Meta-analyses of patients taking VEGF 
inhibitors revealed that the incidence of arterial thrombotic events was 1.4-3.3% with a 
relative risk compared to control of 1.4-3.0 (47–49), while the incidence of venous thrombotic 
events was 2.8-11.9% with a relative risk of 1.1-1.3 compared to control (50,51). 
The vascular endothelium is involved in the regulation and maintenance of vascular 
homeostasis and prevents abnormal blood clotting and bleeding. VEGF plays a considerable 
role in the maintenance of vascular integrity by activating survival and anti-apoptotic 
signaling (52,53). VEGF inhibition can interfere with the regenerative capacity of endothelial 
cells and cause defects of the endothelial layer that expose the highly prothrombotic basement 
membrane (32,54). Exposure to subendothelial von Willebrand factor and tissue factor initiate 
platelet aggregation and the coagulation cascade (54). VEGF also increases the bioavailability 
of prostacyclin and NO, both of which have antiplatelet activities and promote thrombosis 
when inhibited (32).  
 
3. BCR-ABL tyrosine kinase inhibitors 
For most patients with chronic myeloid leukemia (CML), small-molecule tyrosine kinase 
inhibitors (TKIs) have turned a fatal disease into a manageable chronic condition. Imatinib, 
the first BCR-ABL TKI granted regulatory approval, inhibits ABL kinase as well as 
proto-oncogene c-KIT and platelet-derived growth factor receptor (PDGFR). Newer 
generations of BCR-ABL kinase inhibitors (dasatinib, nilotinib, bosutinib, and ponatinib) 
have been developed to overcome imatinib resistance or intolerance (55). Cardiovascular 
safety is an emerging challenge in patients treated with newer generations of BCR-ABL 
inhibitors. 
 Cardiovascular toxicity is rare with imatinib; in fact, imatinib may have beneficial 
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roles in the vasculature. Long-term observations from phase III studies have revealed a lower 
incidence of peripheral arterial disease in patients treated with imatinib compared with 
patients not treated with TKI or treated with nilotinib (56). A randomized double-blind 
placebo-controlled trial reported that imatinib significantly improved exercise capacity, 
hemodynamics, and right ventricular function in patients with pulmonary hypertension 
(57,58).  
 
3.1. Pulmonary hypertension 
In contrast to imatinib, dasatinib is known to cause drug-induced pulmonary hypertension at 
an estimated lowest incidence of 0.45% and a median delay between drug initiation and 
pulmonary hypertension diagnosis of 34 months (range, 8-48 months) (59). At diagnosis, 
most patients had severe clinical, functional and hemodynamic signs of impairment with 
minimal acute vasodilator response, some of which required vasoactive drugs and intensive 
care unit management (59). Clinical and functional improvements were usually observed after 
dasatinib discontinuation; however, the majority of patients failed to demonstrate complete 
hemodynamic recovery, and some died of sudden death or cardiac failure during follow-up 
(59). The mechanism of dasatinib-associated pulmonary hypertension is not yet completely 
understood. One possible mechanism behind dasatinib-induced pulmonary hypertension is 
that dasatinib causes pulmonary vascular endothelial cell damage, endoplasmic reticulum 
stress, and mitochondrial reactive oxygen species production, which leads to increased 
susceptibility to the development of pulmonary hypertension (60). Interestingly, dasatinib is 
associated with a higher incidence of pleural effusion, reportedly, 14-39% (61). The presence 
of symptoms (i.e., chest pain, dyspnea, dry cough, syncope) not explained by pleural effusion 
should prompt the suspicion of pulmonary hypertension. Although rare, it is potentially fatal. 
The prompt withdrawal of dasatinib may completely or partially reverse pulmonary 
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hypertension, but pharmacologic treatment may be needed and the referral to a suitable 
specialist is mandatory (61). 
 
3.2. Vascular adverse events 
Vascular events including cardiac and cerebral ischemic events and peripheral arterial 
occlusive disease have become an emerging new type of toxicity in CML patients treated with 
ponatinib and nilotinib (61,62). The rates of vascular adverse events in clinical trials varied 
considerably because the trials were not designed to assess this point, and vascular risk factors 
were not properly assessed before and during the treatment. After a 2-year observation time, 
the percentage of CML patients developing vascular adverse events during nilotinib was 
reportedly 1-29% (62). A prospective study involving 159 patients on imatinib or nilotinib 
showed a higher incidence of abnormal ankle-brachial index (ABI) in patients on nilotinib 
(relative risk, 10.3). The incidence of abnormal ABI in patients treated with first- and 
second-line nilotinib was 26% and 36%, respectively, compared with 6.3% for first-line 
imatinib (63). In a recent study using the the French Pharmacovigilance Database, 25 cases 
with peripheral aortic obstructive disease were identified, and the mean time from initiation of 
nilotinib to the event onset was 24 months (64). The frequency of arterial occlusive events in 
patients treated with ponatinib in the Evaluation of Ponatinib versus Imatinib in Chronic 
Myeloid Leukemia (EPIC) study was 7.1% compared with 2.0% for imatinib after a median 
follow-up of 5.1 months (65). Notably, median time to onset of first arterial occlusive event 
was 3.6 months for ponatinib-treated patients. In the phase 2 trial of ponatinib in refractory 
CML, arterial occlusive events were observed in 27% of patients after a median follow-up of 
38 months, in which the median time to onset was 11 months (66). Thus, in contrast to other 
vascular toxic agents, e.g. tobacco, steroids, BCR-ABL TKIs seem to affect vascular 
homeostasis more rapidly. All patients receiving these agents should undergo cardiovascular 
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assessment repeatedly. 
The mechanisms behind the vascular toxicity of nilotinib and ponatinib remain 
unclear. Several clinical studies suggest that nilotinib is associated with hyperglycemia and 
hypercholesterolemia (61), which are major risk factors for developing atherosclerosis. 
Nilotinib may accelerate atherosclerosis, leading to ischemic vascular adverse events. Given 
the high frequency of vascular adverse events associated with nilotinib and ponatinib, in the 
first-line treatment of chronic-phase CML in patients at very high risk of cardiovascular 
disease, imatinib or dasatinib seems to be the preferred option.  
 
4. Future directions 
Without question, targeted therapies have revolutionized the treatment of cancer across 
multiple histologies. Therefore, the cardiac impact of targeted therapies is a critically 
important topic of discussion, not only for the practicing oncologist as well as cardiologists 
and researchers. Awareness of the potential side effects, recognition of the signs and 
symptoms, and establishment of therapeutic strategies are all crucial for providing quality 
patient care. Long-term follow-up is needed as the field continues to improve survival 
outcomes with new and exciting therapies.  
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Figure Legends 
Figure 1. Schematic diagram of ErbB2 downstream signalling pathways and modulators 
regulating cardiomyocyte dedifferentiation, proliferation, contraction, and hypertrophic 
growth.  
Neuregulin-1 (NRG-1) secreted from endothelial cells binds to ErbB4, induces 
phosphorylation of ErbB2/ErbB4 heterodimers, and is expressed in cardiomyocytes. This 
results in cell signaling through the Ras/ERK, Src/FAK, and PI3K/AKT pathways, which 
leads to cardiomyocyte proliferation, hypertrophy, dedifferentiation, and 
contraction. Trastuzumab and pertuzumab bind to the ErbB2, while lapatinib binds the 
intracellular adenosine triphosphate binding domain of ErbB2, which results in cell signaling 
inhibition. 
 
Figure 2. Mechanisms of VEGF signaling pathway inhibitor-induced cardiovascular 
toxicities.  
VEGF binding to VEGF receptors initiates a tyrosine kinase signaling cascade that leads to 
increased proliferation, survival, permeability, and migration. VEGF inhibitors induce an 
imbalance between vasodilation and vasoconstriction by reducing NO and PGI2 and 
increasing ET-1 and, as a consequence, increase peripheral vascular resistance and blood 
pressure.  
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Table 
Table 1. Targeted cancer therapies and associated cardiovascular toxic effects 
Drug Molecular target Class Cancer type Cardiovascular toxic effects 
HER2 inhibitors     
Trastuzumab HER2 mAb Breast cancer, gastric cancer LVD, HF 
Pertuzumab HER2 mAb Breast cancer LVD, HF 
Lapatinib HER2, EGFR TKI Breast cancer LVD, HF 
Trastuzumab emtansine 
(T-DM1) 
HER2, tubulin Antibody-drug 
conjugate 
Breast cancer LVD, HF 
VEGF signaling pathway 
inhibitors 
    
Bevacizumab VEGFA mAb Colorectal cancer, NSCLC, 
RCC, ovarian cancer, cervical 
cancer, glioblastoma 
multiforme, breast cancer 
HTN, stroke, MI 
Aflibercept VEGFA, VEGFB, VEGF trap Colorectal cancer HTN, ATE 
25 
PIGF 
Ramucirumab VEGFR2 mAb Colorectal cancer, gastric 
cancer, NSCLC 
HTN, ATE 
Sunitinib VEGFRs, PDGFRs, 
FLT3, CSF1R 
TKI RCC, GIST, pancreatic 
neuroendocrine tumors 
HTN, QTc prolongation, 
torsade de points, ATE, VTE, 
HF 
Sorafenib VEGFRs, PDGFRs, 
FLT3, RAF1, BRAF 
TKI RCC, hepatic cell carcinoma, 
thyroid cancer 
HTN, ATE, VTE, HF 
Pazopanib VEGFR1, VEGFR3, 
PDGFRs, c-KIT 
TKI RCC, soft-tissue sarcoma HTN, QTc prolongation, 
torsade de points, ATE, VTE 
Axitinib VEGFRs, PDGFRs, 
FLT3, CSF1R 
TKI RCC HTN, ATE, LVD 
Vandetanib VEGFR2, EGFR, RET TKI Medullary thyroid cancer HTN, QTc prolongation, 
torsade de points, sudden 
death 
Regorafenib VEGFRs, RET, c-KIT TKI Colorectal cancer, GIST HTN, ischemic heart disease 
26 
PDGFR, RET, RAF, 
FGFR 
BCR-ABL TKIs     
Bosutinib BCR-ABL, Src family TKI CML Pericardial effusion, 
pulmonary edema  
Dasatinib BCR-ABL, PDGFR, 
c-KIT, Src family 
TKI CML, Ph+ALL Pulmonary artery 
hypertension, pleural effusion 
Nilotinib BCR-ABL, PDGFR, 
c-KIT 
TKI CML QTc prolongation, CAD, PAD 
Ponatinib BCR-ABL, FGFR, 
VEGFR, PDGFR, Src 
family, c-KIT, RET, 
FLT3 
TKI CML, Ph+ALL HTN, CAD, PAD, stroke, 
VTE, atrial fibrillation 
ALL, acute lymphocytic leukemia; CAD, coronary artery disease; CML, chronic myeloid leukemia; CSF1R, colony stimulating factor-1 
receptor; EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; GIST, gastrointestinal stromal tumor; HER2, human 
epidermal growth factor receptor 2; HF, heart failure; HTN, hypertension; LVD, left ventricular dysfunction; mAb; monoclonal antibody; MI, 
27 
myocardial infarction; NSCLC, non-small cell lung cancer; PAD, peripheral artery disease; PDGFR, platelet-derived growth factor receptor; Ph, 
Philadelphia chromosome; RCC, renal cell carcinoma; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor; VEGFR, VEGF 
receptor; VTE, venous thromboembolism 
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